The disclosure provides processes for preparing 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile and for preparing sulindac, relating to the field of medicine. The former comprises mixing 6-fluoro-2-methyl-1-indanone, cyanoacetic acid, a first organic solvent and an acetic acid-based catalyst to proceed with a first condensation reaction to give a first condensation reaction solution, which contains 5-fluoro-2-methyl-3-indanacetonitrile; and mixing the first condensation reaction solution, per se, with a base, a second organic solvent and 4-(methylthio)benzaldehyde to proceed with a second condensation reaction to give 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile. The process is a one-pot process without separation of 5-fluoro-2-methyl-3-indanacetonitrile from the solvent, shortening the synthetic route, simplifying the preparation process and improving the 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile yield.

The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R.sub.1 is COOR.sub.4, (CH.sub.2)nCOOR.sub.4, SO.sub.3H, (CH.sub.2)nSO.sub.3H or CONH—R.sub.10; one of R.sub.2 and R.sub.3 is H and the other is R.sub.5.

##STR00001##

The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R.sub.1 is COOR.sub.4, (CH.sub.2)nCOOR.sub.4, SO.sub.3H, (CH.sub.2)nSO.sub.3H or CONH—R.sub.10; one of R.sub.2 and R.sub.3 is H and the other is R.sub.5.

##STR00001##

The present application relates to compounds according to (Formula IA) or (Formula IB): ##STR00001## or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORγ and are useful for the treatment of RORγ mediated diseases.

The present application relates to compounds according to (Formula IA) or (Formula IB): ##STR00001## or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORγ and are useful for the treatment of RORγ mediated diseases.

The present invention relates to disubstituted 5(3)-pyrazole carboxylates of the formula (Ia) or (Ib) and a process for their preparation

##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n are defined as above.

The present invention relates to disubstituted 5(3)-pyrazole carboxylates of the formula (Ia) or (Ib) and a process for their preparation

##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n are defined as above.

The disclosure provides processes for preparing 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile and for preparing sulindac, relating to the field of medicine. The former comprises mixing 6-fluoro-2-methyl-1-indanone, cyanoacetic acid, a first organic solvent and an acetic acid-based catalyst to proceed with a first condensation reaction to give a first condensation reaction solution, which contains 5-fluoro-2-methyl-3-indanacetonitrile; and mixing the first condensation reaction solution, per se, with a base, a second organic solvent and 4-(methylthio)benzaldehyde to proceed with a second condensation reaction to give 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile. The process is a one-pot process without separation of 5-fluoro-2-methyl-3-indanacetonitrile from the solvent, shortening the synthetic route, simplifying the preparation process and improving the 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile yield.

The present invention relates to disubstituted 3-pyrazole carboxylates of the formula (I) and a process for their preparation

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n are defined as above.

The present invention relates to disubstituted 3-pyrazole carboxylates of the formula (I) and a process for their preparation

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n are defined as above.